WO1998024482A3 - Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung - Google Patents

Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung Download PDF

Info

Publication number
WO1998024482A3
WO1998024482A3 PCT/EP1997/006518 EP9706518W WO9824482A3 WO 1998024482 A3 WO1998024482 A3 WO 1998024482A3 EP 9706518 W EP9706518 W EP 9706518W WO 9824482 A3 WO9824482 A3 WO 9824482A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
endothelin
therapy
processes
substances containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/006518
Other languages
English (en)
French (fr)
Other versions
WO1998024482A2 (de
Inventor
Ludger Dinkelborg
Ulrich Speck
Christoph-Stephan Hilger
Friedhelm Blume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to AU55545/98A priority Critical patent/AU5554598A/en
Priority to EP97951940A priority patent/EP0946205A2/de
Priority to JP52513698A priority patent/JP2001504841A/ja
Publication of WO1998024482A2 publication Critical patent/WO1998024482A2/de
Publication of WO1998024482A3 publication Critical patent/WO1998024482A3/de
Anticipated expiration legal-status Critical
Priority to US09/988,008 priority patent/US20030119719A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Konjugaten aus Endothelinen und Wirkgruppen zur Therapie von Gefäßerkrankungen, sowie neue Endothelin-Konjugate, diese Verbindungen enthaltende Mittel und Verfahren zu ihrer Herstellung.
PCT/EP1997/006518 1996-10-04 1997-11-24 Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung Ceased WO1998024482A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU55545/98A AU5554598A (en) 1996-12-04 1997-11-24 Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them
EP97951940A EP0946205A2 (de) 1996-12-04 1997-11-24 Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
JP52513698A JP2001504841A (ja) 1996-12-04 1997-11-24 治療におけるエンドセリン複合体の使用、新規のエンドセリン複合体、該物質を含有する薬剤、ならびにその製造方法
US09/988,008 US20030119719A1 (en) 1996-10-04 2001-11-16 Use of endothelin conjugates in therapy, new endothelin conjugates, agents that contain the latter, and process for their production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19652374A DE19652374A1 (de) 1996-12-04 1996-12-04 Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
DE19652374.5 1996-12-04

Publications (2)

Publication Number Publication Date
WO1998024482A2 WO1998024482A2 (de) 1998-06-11
WO1998024482A3 true WO1998024482A3 (de) 1999-04-01

Family

ID=7814923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006518 Ceased WO1998024482A2 (de) 1996-10-04 1997-11-24 Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung

Country Status (6)

Country Link
US (1) US20030119719A1 (de)
EP (1) EP0946205A2 (de)
JP (1) JP2001504841A (de)
AU (1) AU5554598A (de)
DE (1) DE19652374A1 (de)
WO (1) WO1998024482A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214734T3 (es) * 1997-09-26 2004-09-16 ABBOTT GMBH & CO. KG Antagonista de la endotelina e inhibidor del sistema renina-angiotensina como preparado de combinacion.
DE19743143A1 (de) * 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19916417A1 (de) * 1999-04-01 2000-10-19 Schering Ag Amyloidspezifisches Aptamer
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019644A1 (fr) * 1991-04-24 1992-11-12 Banyu Pharmaceutical Co., Ltd. Peptide vasodilatateur
EP0547317A1 (de) * 1991-12-19 1993-06-23 Takeda Chemical Industries, Ltd. Endothelin Antagonisten
EP0548441A1 (de) * 1991-12-23 1993-06-30 Japat Ltd Endothelin-Antagoniste
US5260276A (en) * 1991-06-14 1993-11-09 Warner-Lambert Company Linear and monocyclic endothelin antagonists
WO1993021945A1 (en) * 1992-04-23 1993-11-11 The Regents Of The University Of California METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b)
EP0603399A1 (de) * 1991-12-27 1994-06-29 Kyowa Hakko Kogyo Kabushiki Kaisha Peptide als antagonisten des endothelin
DE4301871A1 (de) * 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
DE4311023A1 (de) * 1993-03-31 1994-10-06 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
DE4311022A1 (de) * 1993-03-31 1994-10-06 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
DE4310999A1 (de) * 1993-03-31 1994-10-06 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
WO1994022491A1 (de) * 1993-03-31 1994-10-13 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Bifunktionelle chelatbildner und ihre anwendung in der radiopharmazeutik
WO1995003795A1 (en) * 1993-07-29 1995-02-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
DE4337599A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0679658A1 (de) * 1993-06-25 1995-11-02 Kyowa Hakko Kogyo Co., Ltd. Endothelinantagonisierendes peptid
DE4425778A1 (de) * 1994-07-13 1996-01-18 Diagnostikforschung Inst Komplexverbindungen zur Diagnose von Gefäßerkrankungen
DE4428851A1 (de) * 1994-08-04 1996-02-08 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
EP0716836A1 (de) * 1994-12-13 1996-06-19 Advanced Cardiovascular Systems, Inc. Polymerfilm zum Umhüllen einer Stentstruktur
WO1997010852A2 (de) * 1995-09-21 1997-03-27 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsns für radioaktive isotope
WO1997010853A2 (de) * 1995-09-21 1997-03-27 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Bifunktionelle nicotinamid-chelatbildner vom typ n2s2 für radioaktive isotope
WO1997012850A2 (de) * 1995-09-21 1997-04-10 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsny für radioaktive isotope
WO1997033608A2 (en) * 1996-03-13 1997-09-18 Queen's University At Kingston Antagonism of endothelin actions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4504476A (en) * 1983-09-16 1985-03-12 Arnold Schwartz Method of administering calcium channel blocking agents
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
DE69212011T2 (de) * 1991-02-15 1997-01-09 Takeda Chemical Industries Ltd Endothelin Antagoniste
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
KR0133372B1 (ko) * 1991-09-06 1998-04-23 고야 다다시 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US5639860A (en) * 1991-12-27 1997-06-17 Kyowa Hakko Kogyo Co., Ltd. Endothelin-antagonizing peptide
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019644A1 (fr) * 1991-04-24 1992-11-12 Banyu Pharmaceutical Co., Ltd. Peptide vasodilatateur
US5260276A (en) * 1991-06-14 1993-11-09 Warner-Lambert Company Linear and monocyclic endothelin antagonists
EP0547317A1 (de) * 1991-12-19 1993-06-23 Takeda Chemical Industries, Ltd. Endothelin Antagonisten
EP0548441A1 (de) * 1991-12-23 1993-06-30 Japat Ltd Endothelin-Antagoniste
EP0603399A1 (de) * 1991-12-27 1994-06-29 Kyowa Hakko Kogyo Kabushiki Kaisha Peptide als antagonisten des endothelin
WO1993021945A1 (en) * 1992-04-23 1993-11-11 The Regents Of The University Of California METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b)
DE4301871A1 (de) * 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
WO1994022491A1 (de) * 1993-03-31 1994-10-13 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Bifunktionelle chelatbildner und ihre anwendung in der radiopharmazeutik
DE4311022A1 (de) * 1993-03-31 1994-10-06 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
DE4310999A1 (de) * 1993-03-31 1994-10-06 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
DE4311023A1 (de) * 1993-03-31 1994-10-06 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
EP0679658A1 (de) * 1993-06-25 1995-11-02 Kyowa Hakko Kogyo Co., Ltd. Endothelinantagonisierendes peptid
WO1995003795A1 (en) * 1993-07-29 1995-02-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
DE4337599A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4425778A1 (de) * 1994-07-13 1996-01-18 Diagnostikforschung Inst Komplexverbindungen zur Diagnose von Gefäßerkrankungen
WO1996002568A1 (de) * 1994-07-13 1996-02-01 Institut Für Diagnostikforschung Gmbh Komplexverbindungen zur diagnose von gefässerkrankungen
DE4428851A1 (de) * 1994-08-04 1996-02-08 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
EP0716836A1 (de) * 1994-12-13 1996-06-19 Advanced Cardiovascular Systems, Inc. Polymerfilm zum Umhüllen einer Stentstruktur
WO1997010852A2 (de) * 1995-09-21 1997-03-27 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsns für radioaktive isotope
WO1997010853A2 (de) * 1995-09-21 1997-03-27 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Bifunktionelle nicotinamid-chelatbildner vom typ n2s2 für radioaktive isotope
WO1997012850A2 (de) * 1995-09-21 1997-04-10 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsny für radioaktive isotope
WO1997033608A2 (en) * 1996-03-13 1997-09-18 Queen's University At Kingston Antagonism of endothelin actions

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Radiopharmaceuticals", REYNOLDS J E F ET AL. (ED): MARTINDALE - THE EXTRA PHARMACOPOEIA, ED. 31, 1996, Royal Pharmaceutical Society, London, GB, pages 1463 - 1468, XP002075389 *
ACHMAD T.H. ET AL: "Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers", BIOCHEM. BIOPHYS. RES. COMMUN., 1992, VOL. 189, NO. 2, PAGE(S) 994-1000, XP002086785 *
BARRY W.L. ET AL: "Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty", CARDIOL. CLIN., 1994, VOL. 12, NO. 3, PAGE(S) 517-535, XP002086786 *
BOGER R.H. ET AL: "Restenosis after percutaneous transluminal angioplasty: II. Posibilities for pharmacological intervention", VASA - JOURNAL OF VASCULAR DISEASES, 1996, VOL. 25, NO. 1, PAGE(S) 21-31, XP002086789 *
BOULANGER C.M. ET AL: "Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta", CIRC. RES., 1991, VOL. 68, NO. 6, PAGE(S) 1768-1772, XP002086782 *
HEDIN U. ET AL: "Heparin inhibits thrombin-induced mitogen-activated protein kinase signaling in arterial smooth muscle cells", JOURNAL OF VASCULAR SURGERY, 1998, VOL. 27, NO. 3, PAGE(S) 512-520, XP002086790 *
HEYL D L ET AL: "TRUNCATED ANALOGUES OF ENDOTHELIN AND SARAFOTOXIN ARE SELECTIVE FOR THE ETB RECEPTOR SUBTYPE", PEPTIDE RESEARCH, vol. 6, no. 5, September 1993 (1993-09-01), pages 238 - 241, XP000647827 *
KATAHIRA R ET AL: "STRUCTURAL STUDIES ON ENDOTHELIN RECEPTOR SUBTYPE B SPECIFIC AGONIST IRL 1620 SUC- GLU9, ALA 11,15ET-1(8-21) AND ITS ANALOGS WITH DIPALMITOYL PHOSPHATIDYLCHOLINE VESICLES BY NMR SPECTROSCOPY", JOURNAL OF PEPTIDE RESEARCH, vol. 51, no. 2, February 1998 (1998-02-01), pages 155 - 161, XP000730044 *
LAURENT S. ET AL: "LA PAROI ARTERIELLE: UNE NOUVELLE CIBLE PHARMACOLOGIQUE ET THERAPEUTIQUE?", THERAPIE, 1995, VOL. 50, NO. 4, PAGE(S) 387-398, XP002086787 *
LUSCHER TF ET AL: "Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.", DRUGS, 1993, VOL. 46, SUPPL 2, PAGE(S) 121-132, XP002086784 *
MAGAZINE H I ET AL: "EVALUATION OF ENDOTHELIN RECEPTOR POPULATIONS USING ENDOTHELIN-1 BIOTINYLATED AT LYSINE-9 SIDECHAIN", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 181, no. 3, 31 December 1991 (1991-12-31), pages 1245 - 1250, XP002029500 *
SCHVARTZ I ET AL: "BIOTINYLATED ENDOTHELIN AS A PROBE FOR THE ENDOTHELIN RECEPTOR", PEPTIDES, vol. 12, no. 6, 1 January 1991 (1991-01-01), pages 1229 - 1233, XP000578529 *
SHAW L.A. ET AL: "Pharmacological inhibition of restenosis: Learning from experience", TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, VOL. 16, NO. 12, PAGE(S) 401-404, XP002086788 *
YANG Z. ET AL: "17beta-Oestradiol inhibits growth of human vascular smooth muscle: Similar effects in cells from females and males", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, APRIL 1996, VOL. 28, SUPPL. 5, PAGE(S) S34-S39, XP002086783 *

Also Published As

Publication number Publication date
JP2001504841A (ja) 2001-04-10
US20030119719A1 (en) 2003-06-26
WO1998024482A2 (de) 1998-06-11
DE19652374A1 (de) 1998-06-10
EP0946205A2 (de) 1999-10-06
AU5554598A (en) 1998-06-29

Similar Documents

Publication Publication Date Title
WO1996040055A3 (en) Biological agent compositions
AP9801392A0 (en) Concentrated antibody preparation.
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
AU3310595A (en) Compositions and methods for identifying biologically active molecules
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
AU6564794A (en) Use of nona- and decapeptides in the preparation of a drug for the treatment of aids
IE960853L (en) Vascular anticoagulant proteins
WO1996003515A3 (en) Surface expression of enzyme in gene directed prodrug therapy
ZA9810841B (en) Expoxidation catalyst, its use and epoxidation process in the presence of this catalyst.
WO2003030927A3 (fr) Utilisation de peptides analogues de la thymuline (pat) pour la fabrication de medicaments contre la douleur
AU2508597A (en) Drug for the treatment of tumours
AU1873599A (en) Stent for implantation in the human body, especially in blood vessels
AU3262797A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
AU1594897A (en) Solid instant-release forms of administration and process for producing the same
WO1998024482A3 (de) Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
WO1997026918A3 (en) Ligand directed enzyme prodrug therapy
AU2668400A (en) Human antibiotic proteins
EP0967276A3 (de) Antitumor-Mittel dass Salmosin enthält
AU7595298A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension
ZA9810842B (en) Epoxidation catalyst, its use and epoxidation process in the presence of this catalyst.
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
WO1998006409A3 (de) Vitamin a-haltige zusammensetzung und deren verwendung insbesondere gegen hauterkrankungen
ITRM930818A0 (it) Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
NZ514691A (en) Method to type prion proteins
SI0980251T1 (en) Tissue factor for influencing blood vessel formation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1997951940

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 525136

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997951940

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09319414

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1997951940

Country of ref document: EP